Mistletoe lectin I-induced effects on human cytotoxic lymphocytes. I. Synergism with IL-2 in the induction of enhanced LAK cytotoxicity

被引:35
作者
Baxevanis, CN
Voutsas, LF
Soler, MH
Gritzapis, AD
Tsitsilonis, OE
Stoeva, S
Voelter, W
Arsenis, P
Papamichail, M
机构
[1] St Savas Canc Hosp, Canc Immunol & Immunotherapy Ctr, Athens 11522, Greece
[2] Univ Tubingen, Inst Physiol Chem, Phys Biochem Abt, D-72076 Tubingen, Germany
关键词
D O I
10.3109/08923979809034819
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
This report demonstrates that in vitro activation of human cells with the beta-galactoside-specific lectin from mistletoe (ML-I) or interleukin-2 (IL-2) results in different patterns of activation and function of cytotoxic cells. It is now well established that natural killer (NK) and lymphokine-activated killer (LAK) cytotoxicity is mainly mediated by resting (NK) and IL-2-activated (LAK) CD56-positive (+) cells respectively. Culture of peripheral blood lymphocytes (PBL) for 3 days with ML-I led to expansion and activation of T cells which demonstrated NK- and LAK-like cytotoxicity. T lymphocyte subset analysis revealed that in total PBL, ML-I preferentially stimulated and expanded CD8+ T cells which mediated the cytotoxic effect. Incubation of highly purified CD8+ T cells alone with ML-I did not lead to induction of cytotoxicity, which required the presence of both CD4+ and CD14+ (monocytes) cells, suggesting that ML-I does not exert a direct effect on CD8+ T cells. Activation of PBL with both ML-I and IL-2 resulted in simultaneous induction of T and CD56+ cell-mediated NK and LAK cytotoxicity. These data suggest that treatment with ML-I and IL-2 might provide an approach to induce maximum cytotoxicity against tumors and to recruit both T and NK cells for tumor therapy.
引用
收藏
页码:355 / 372
页数:18
相关论文
共 31 条
[1]   TCR-GAMMA-DELTA BEARING LYMPHOCYTES-T INFILTRATING HUMAN PRIMARY CUTANEOUS MELANOMAS [J].
BACHELEZ, H ;
FLAGEUL, B ;
DEGOS, L ;
BOUMSELL, L ;
BENSUSSAN, A .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1992, 98 (03) :369-374
[2]  
BAXEVANIS CN, 1995, CANCER, V76, P1253, DOI 10.1002/1097-0142(19951001)76:7<1253::AID-CNCR2820760724>3.0.CO
[3]  
2-F
[4]  
BAXEVANIS CN, 1993, CANCER-AM CANCER SOC, V72, P491, DOI 10.1002/1097-0142(19930715)72:2<491::AID-CNCR2820720227>3.0.CO
[5]  
2-1
[6]   CHARACTERIZATION OF THE ANTITUMOR IMMUNE-RESPONSE IN HUMAN CANCERS AND STRATEGIES FOR IMMUNOTHERAPY [J].
BAXEVANIS, CN ;
PAPAMICHAIL, M .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 1994, 16 (03) :157-179
[7]  
BAXEVANIS CN, 1994, CANCER, V74, P1275, DOI 10.1002/1097-0142(19940815)74:4<1275::AID-CNCR2820740416>3.0.CO
[8]  
2-Q
[9]   INTERLEUKIN-1-BETA SYNERGISES WITH INTERLEUKIN-2 IN THE OUTGROWTH OF AUTOLOGOUS TUMOR-REACTIVE CD8+ EFFECTORS [J].
BAXEVANIS, CN ;
DEDOUSSIS, GVZ ;
GRITZAPIS, AD ;
STATHOPOULOS, GP ;
PAPAMICHAIL, M .
BRITISH JOURNAL OF CANCER, 1994, 70 (04) :625-630
[10]  
BEUTH J, 1995, ARZNEIMITTEL-FORSCH, V45-1, P505